Nicollet Mall

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Retrieved on:

Tuesday, February 13, 2024

Attention, Jefferies Group, Prospectus, Telephone, Cardiovascular disease, RBC Capital Markets, Sale, Equity capital markets, Form, Nicollet Mall, Risk, NAMS, State Street, SVB Securities, Madison Avenue, Patient, Common stock, Vesey Street

NAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of the Company’s ordinary shares, with a nominal value of €0.12 per share (“Ordinary Shares,”) and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” such offering, the “Offering”).

Key Points:

NAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of the Company’s ordinary shares, with a nominal value of €0.12 per share (“Ordinary Shares,”) and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” such offering, the “Offering”).
All Ordinary Shares and Pre-Funded Warrants to be sold in the proposed Offering will be sold by the Company.
In addition, the Company expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exceed 15% of the securities sold in the proposed Offering.
Jefferies, Leerink Partners, Piper Sandler, and RBC Capital Markets are acting as joint book-running managers for the proposed Offering.

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on:

Monday, January 29, 2024

Jefferies, Patient, Madison Avenue, Guggenheim Partners, Jefferies Group, TRML, Nicollet Mall, Floor, Prospectus, Form, Sale, Tourmaline, S-3, Inflammation, Attention, Telephone, Exercise, Security (finance)

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $172.5 million.

Key Points:

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $172.5 million.
All shares of common stock were offered by Tourmaline.
Following the closing of the offering, Tourmaline has 25,645,262 shares of common stock issued and outstanding as of January 29, 2024.
Jefferies, Piper Sandler, Guggenheim Securities and Truist Securities acted as joint book-running managers for the offering.

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

Retrieved on:

Thursday, January 25, 2024

Jefferies, Patient, Madison Avenue, Guggenheim Partners, Jefferies Group, TRML, Nicollet Mall, Floor, Prospectus, Form, Sale, Tourmaline, S-3, Inflammation, Truist, Attention, Telephone, Security (finance)

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, at a public offering price of $32.50 per share.

Key Points:

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, at a public offering price of $32.50 per share.
The gross proceeds to Tourmaline from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $150.0 million.
All of the common stock is being offered by Tourmaline.
In addition, Tourmaline has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of common stock at the public offering price, less the underwriting discounts and commissions.

Tourmaline Bio Announces Proposed Public Offering of Common Stock

Retrieved on:

Wednesday, January 24, 2024

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the launch of a proposed underwritten public offering of its common stock.

Key Points:

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the launch of a proposed underwritten public offering of its common stock.
All shares of common stock to be sold in the proposed offering will be sold by Tourmaline.
In addition, Tourmaline expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exceed 15% of the number of shares of common stock sold in the offering.
The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

Retrieved on:

Thursday, January 11, 2024

Nicollet Mall, Form, Sale, Form S-3, Central nervous system, Telephone, Attention, Praxis, Security (finance), CNS

The gross proceeds from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.

Key Points:

The gross proceeds from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.
All shares and pre-funded warrants in the offering are being offered by Praxis.
In addition, Praxis has granted the underwriters a 30-day option to purchase up to 633,750 additional shares of common stock at the public offering price, less the underwriting discount and commission.
The offering is expected to close on or about January 16, 2024, subject to market conditions and the satisfaction of customary closing conditions.

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Retrieved on:

Wednesday, January 10, 2024

Nicollet Mall, Form, Sale, Form S-3, Central nervous system, Telephone, Attention, Praxis, Security (finance), CNS

All securities in the offering will be offered by Praxis.

Key Points:

All securities in the offering will be offered by Praxis.
In addition, Praxis intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount up to 15% of the shares of common stock (or prefunded warrants in lieu thereof) sold in the offering at the public offering price, less the underwriting discount and commission.
The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed.
The proposed offering will be made only by means of a preliminary prospectus supplement and the accompanying base prospectus.

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

Retrieved on:

Tuesday, January 9, 2024

Patient, Therapy, SVB Securities, Nicollet Mall, Prospectus, Form, Sale, Disorder, S-3, Protein, Telephone, Attention, KROS, Option, State Street, Exercise, Security (finance), File

The net proceeds to Keros from the offering, before deducting offering expenses, were approximately $151.3 million.

Key Points:

The net proceeds to Keros from the offering, before deducting offering expenses, were approximately $151.3 million.
All of the common stock was offered by Keros.
Goldman Sachs & Co. LLC, Leerink Partners, Piper Sandler and Truist Securities acted as joint book-running managers for the offering.
A final prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on January 4, 2024, and is available on the SEC’s website at www.sec.gov.

Zip 2023 in Review: $100 Million Series C, Intake-to-Pay Expansion, Inaugural User Conference ‘Zip Forward’, and New Generative AI Advancements

Retrieved on:

Thursday, January 11, 2024

The past 12 months have not only solidified our position, but also advanced Zip from a promising tech innovator to an established industry leader,” said Rujul Zaparde, CEO and Co-founder of Zip.

Key Points:

The past 12 months have not only solidified our position, but also advanced Zip from a promising tech innovator to an established industry leader,” said Rujul Zaparde, CEO and Co-founder of Zip.
“We built Zip for the new world of procurement where people want more than just a better process.
They want a fully intuitive experience with strong visibility and control across the end-to-end cross functional process—made possible with intake and adoption.
In early November, Zip’s inaugural user conference Zip Forward premiered, bringing together over 400 attendees, including distinguished speakers from Snowflake, OpenAI, Discover, Figma and more.

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Retrieved on:

Thursday, January 4, 2024

Telephone, Protein, Sale, Nicollet Mall, Form, File, KROS, Attention, State Street, Therapy, SVB Securities, S-3, Prospectus, Patient, Truist, Security (finance), Disorder

The gross proceeds to Keros from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $140.0 million.

Key Points:

The gross proceeds to Keros from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $140.0 million.
All of the common stock is being offered by Keros.
In addition, Keros has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.
Goldman Sachs & Co. LLC, Leerink Partners, Piper Sandler and Truist Securities are acting as joint book-running managers for the offering.

Keros Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on:

Wednesday, January 3, 2024

Telephone, Protein, Sale, Nicollet Mall, Form, File, KROS, Attention, State Street, Therapy, SVB Securities, S-3, Keros, Prospectus, Patient, Truist, Security (finance), Disorder

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the launch of a proposed underwritten public offering of $120.0 million of shares of its common stock (the “Offer Shares”).

Key Points:

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the launch of a proposed underwritten public offering of $120.0 million of shares of its common stock (the “Offer Shares”).
All shares of common stock to be sold in the proposed offering will be sold by Keros.
The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC, Leerink Partners, Piper Sandler and Truist Securities are acting as joint book-running managers for the offering.